Trials / Completed
CompletedNCT00265551
Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Olanzapine-Referenced, Parallel Group Safety, Efficacy, and Tolerability Study of SCA-136 in Subjects With Acute Exacerbations of Schizophrenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether a low dose and a high dose of the study drug SCA-136 are effective and safe in the treatment of schizophrenia requiring hospitalization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCA-136 (200 mg) | |
| DRUG | SCA-136 (400 mg) | |
| DRUG | olanzapine (15 mg) | |
| DRUG | placebo |
Timeline
- Start date
- 2006-01-01
- Completion
- 2007-01-01
- First posted
- 2005-12-14
- Last updated
- 2007-12-10
Locations
35 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00265551. Inclusion in this directory is not an endorsement.